Efficacy and safety of olanzapine combined with aprepitant, palonosetron, and dexamethasone for preventing nausea and vomiting induced by cisplatin-based chemotherapy in gynecological cancer: KCOG-G1301 phase II trial

被引：51

作者：

Abe, Masakazu ^{[1
]}

Hirashima, Yasuyuki ^{[1
]}

Kasamatsu, Yuka ^{[1
]}

Kado, Nobuhiro ^{[1
]}

Komeda, Satomi ^{[1
]}

Kuji, Shiho ^{[1
]}

Tanaka, Aki ^{[1
]}

Takahashi, Nobutaka ^{[1
]}

Takekuma, Munetaka ^{[1
]}

Hihara, Hanako ^{[2
]}

Ichikawa, Yoshikazu ^{[2
]}

Itonaga, Yui ^{[3
]}

Hirakawa, Tomoko ^{[3
]}

Nasu, Kaei ^{[3
]}

Miyagi, Kanoko ^{[4
]}

Murakami, Junko ^{[4
]}

Ito, Kimihiko ^{[4
]}

机构：

[1] Shizuoka Canc Ctr, Dept Gynecol, Shizuoka 4118777, Japan

[2] Japanese Red Cross Shizuoka Hosp, Dept Obstet & Gynecol, Shizuoka, Shizuoka 4200853, Japan

[3] Oita Univ, Fac Med, Dept Obstet & Gynecol, Yufu City, Oita 8795593, Japan

[4] Kansai Rousai Hosp, Dept Obstet & Gynecol, Amagasaki, Hyogo 6608511, Japan

来源：

SUPPORTIVE CARE IN CANCER | 2016年 / 24卷 / 02期

关键词：

Olanzapine; Chemotherapy-induced nausea and vomiting; Cisplatin; Highly-emetogenic chemotherapy; Antiemetic therapy; ORAL NEUROKININ-1 ANTAGONIST; PLACEBO-CONTROLLED TRIAL; HIGH-DOSE CISPLATIN; QUALITY-OF-LIFE; EMETOGENIC CHEMOTHERAPY; DELAYED EMESIS; DOUBLE-BLIND; THERAPY; RELIEF;

D O I：

10.1007/s00520-015-2829-z

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Olanzapine is effective in chemotherapy-induced nausea and vomiting (CINV). In patients receiving highly emetogenic chemotherapy (HEC), its efficacy was reported as rescue therapy for breakthrough emesis refractory to triplet therapy (palonosetron, aprepitant, and dexamethasone). However, its preventive effects with triplet therapy for CINV are unknown. This study aimed to investigate efficacy and safety of preventive use of olanzapine with triplet therapy for CINV of HEC. This study is a prospective multicenter study conducted by Kansai Clinical Oncology Group. Forty chemo-na < ve gynecological cancer patients receiving HEC with cisplatin (a parts per thousand yen50 mg/m(2)) were enrolled. Oral olanzapine (5 mg) was administered with triplet therapy a day prior to cisplatin administration and on days 1-5. The primary endpoint was complete response (no vomiting and no rescue) rate for the overall phase (0-120 h post-chemotherapy). Secondary endpoints were complete response rate for acute phase (0-24 h post-chemotherapy) and delayed phase (24-120 h post-chemotherapy) and complete control (no vomiting, no rescue, and no significant nausea) rate and total control (no vomiting, no rescue, and no nausea) rate for each phase. These endpoints were evaluated during the first cycle of chemotherapy. Complete response rates for acute, delayed, and overall phases were 97.5, 95.0, and 92.5 %, respectively. Complete control rates were 92.5, 87.5, and 82.5 %, respectively. Total control rates were 87.5, 67.5, and 67.5 %, respectively. There were no grade 3 or 4 adverse events. Preventive use of olanzapine combined with triplet therapy gives better results than those from previously reported studies of triplet therapy.

引用

页码：675 / 682

页数：8

共 32 条

[31]

Tamura K, 2015, INT J CLIN ONCOL

[32] Clinical research of Olanzapine for prevention of chemotherapy-induced nausea and vomiting [J].

Tan, Lijun ;

Liu, Jiangtao ;

Liu, Xiuli ;

Chen, Jie ;

Yan, Zhijun ;

Yang, Huifen ;

Zhang, Daxin .

JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH, 2009, 28

← 1 2 3 4 →